NCT01808040View on ClinicalTrials.gov

A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

December 9, 2016

Conditions
Post Menopausal, Hormone Receptor Positive Breast Cancer
Interventions
DRUG

TAK700

dose is dependant on dose escalation timepoint and dose expansion cohort dose will be the RP2D determined based on the dose escalation cohort final dose recommendation

Trial Locations (1)

53792

University of Wisconsin, Madison

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

University of Wisconsin, Madison

OTHER